FDA greenlights LivaNova’s nerve stimulation device for epilepsy

The Food and Drug Administration on Friday approved the newest version of LivaNova’s Vagus Nerve Stimulation Therapy System.

Advertisement

The system, used to treat patients with drug-resistant epilepsy, includes the SenTiva implantable generator and a small tablet device used to program the device based on the patient’s treatment needs.

Sentiva can detect and treat seizures before they start, or stop seizures that have already begun by sending electrical impulses to the vagus nerve. The system also collects events commonly associated with seizures, such as heart rate variations or a patient’s body position.

More articles on supply chain:

Express Scripts to acquire eviCore for $3.6B: 4 things to know
This startup will deliver defibrillators to 911 callers via drone
4 drug, devicemakers in the headlines

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.